Ganaxalone Aims to Fill Unmet Need in Status Epilepticus Treatment

Status epilepticus can be one of the most debilitating and hardest to treat neurological conditions. A potential new medication aims to help this patient population through a variety of delivery methods under development.

Albena Patroneva, MD, Chief Medical Officer of Marinus Pharmaceuticals discussed the importance of the development of Ganaxalone during the American Academy of Neurology's annual meeting in Vancouver.

Michael S. Saporito, PhD, noted that there are currently two methods of delivery for ganaxalone being developed, an oral formulation as well as an IV version. If approved both could prove beneficial for treating a dangerous condition.